NEXIEN BIOPHARMA, INC. — Operating Income by Fiscal Year
6 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/b648c083-8c68-4f2d-a7ad-8e113fa3681a/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-11.6M | 2017-03-27 – 2024-09-30 | evidence 0001493152-24-046468 |
| FY 2023 | $11.4M | 2017-03-27 – 2024-03-31 | evidence 0001493152-24-019400 |
| FY 2021 | $10.3M | 2020-07-01 – 2021-06-30 | evidence 0001493152-21-025119 |
| FY 2020 | $8.4M | 2019-07-01 – 2020-06-30 | evidence 0001493152-20-018396 |
| FY 2019 | $6.5M | 2017-03-27 – 2019-09-30 | evidence 0001493152-19-016795 |
| FY 2018 | $4.7M | 2017-03-27 – 2019-03-31 | evidence 0001493152-19-006990 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).